PT-141 Structure-Activity Relationships: How Molecular Modifications Affect Melanocortin Receptor Research Outcomes
PT-141 Structure-Activity Relationships: How Molecular Modifications Affect Melanocortin Receptor Research Outcomes
Last Updated: January 15, 2025
Research Use Only Disclaimer: PT-141 (Bremelanotide) and all structural analogs discussed in this article are sold or referenced exclusively for in vitro laboratory and preclinical research. None of these compounds are intended for human or veterinary use, consumption, or self-administration. This article is provided for scientific and educational reference only.
For researchers designing in vitro experiments or developing novel melanocortin receptor tool compounds, understanding how structural changes to the PT-141 scaffold translate into changes in receptor binding and functional activity is foundational. Structure-activity relationship (SAR) data is what bridges raw chemistry to pharmacological outcomes in the lab. This article reviews what the published preclinical SAR literature tells us about PT-141's scaffold and what it means for melanocortin receptor research design.
What Is SAR and Why Does It Matter for PT-141 Research?
Structure-activity relationships, or SAR, describe the systematic relationship between a compound's chemical structure and its biological activity. For a cyclic peptide like PT-141, SAR data answers questions like:
- Which residues are critical for receptor binding?
- Which positions tolerate modification without loss of activity?
- How do specific structural changes affect selectivity between receptor subtypes (MC1R vs. MC3R vs. MC4R)?
- What structural features drive agonism versus antagonism at melanocortin receptors?
Answering these questions required decades of peptide synthesis and pharmacology work, beginning with alpha-MSH and progressing through the Melanotan compounds to PT-141. The resulting SAR knowledge base makes PT-141 one of the most well-characterized cyclic peptide scaffolds in receptor pharmacology.
The Pharmacophore: Core Residues Required for Receptor Binding
Within PT-141's seven-residue cyclic structure, not all residues contribute equally to receptor binding. The concept of a pharmacophore refers to the minimal set of structural features required for receptor recognition and activation.
For melanocortin peptides generally, the core pharmacophore has been mapped to a tetrapeptide sequence: His-D-Phe-Arg-Trp (corresponding to residues 6-9 in the alpha-MSH numbering system). This sequence is essential and is retained in all active cyclic melanocortin analogs, including PT-141.
Role of Each Pharmacophore Residue
Histidine (His): Contributes to receptor binding through its imidazole side chain, which can participate in hydrogen bonding and electrostatic interactions with receptor binding pocket residues. Replacement of His with alanine substantially reduces binding affinity in published analog studies.
D-Phenylalanine (D-Phe): This residue has two functions: it provides an aromatic side chain that makes hydrophobic contacts in the receptor binding pocket, and its D-configuration is specifically required for high-affinity binding. Substitution with L-Phe reduces activity; substitution with other D-aromatic amino acids (D-Tyr, D-Nal) can modulate receptor subtype selectivity in interesting ways.
Arginine (Arg): The guanidinium side chain of arginine makes critical electrostatic and hydrogen bonding interactions with acidic residues in the MCR binding pocket. Arg is among the most conserved pharmacophore residues; loss of positive charge at this position severely reduces binding affinity across all MCR subtypes.
Tryptophan (Trp): The indole side chain of tryptophan is critical for MC4R engagement in particular. Published SAR work demonstrates that modifications at the Trp position can shift subtype selectivity between MC3R and MC4R, making this an important locus for selectivity engineering.
Structural Features That Affect Receptor Subtype Selectivity
Beyond the pharmacophore, the flanking residues and overall scaffold architecture of PT-141 contribute to its MCR subtype selectivity profile. Several structural features have been identified in the published literature as relevant to selectivity:
C-Terminal Modification (Free Carboxyl vs. Amide)
As discussed in the PT-141 vs. MT-II comparison article, the primary structural difference between PT-141 and MT-II is the C-terminal group: PT-141 has a free carboxyl (-OH) while MT-II has an amide (-NH₂). This modification affects overall molecular charge and hydrogen bonding capacity at the peptide terminus.
In receptor selectivity terms, this difference contributes to PT-141's relatively lower MC1R activity compared to MT-II. The structural basis involves how the C-terminal group interacts with extracellular loop 2 and transmembrane domain contacts in the MC1R binding pocket versus the MC4R binding pocket, which have distinct geometric requirements.
Lactam Bridge Position and Ring Size
The cyclic lactam bridge between Asp and Lys constrains the backbone geometry of the active pharmacophore loop. Published SAR work has explored analogs with modified bridge chemistry, different ring sizes, and alternative bridge positions. In general: - Ring-contracted analogs (smaller cycle) tend to show reduced binding affinity - Ring-expanded analogs can preserve or enhance binding at specific receptor subtypes depending on which residues are affected by the expanded geometry - The Asp-Lys bridge used in PT-141 and MT-II represents an optimized geometry that has been difficult to improve upon while maintaining broad MCR activity
Norleucine at Position 4: Stability vs. Activity
As discussed in the structure article, Nle at position 4 provides metabolic stability without meaningfully affecting receptor binding affinity compared to Met-containing analogs. This represents one of the successful metabolic stabilization strategies in the Melanotan/PT-141 design: modifying a vulnerability (Met oxidation) without paying an activity cost.
From Agonism to Antagonism: How Structure Drives Efficacy
A particularly relevant application of MCR SAR knowledge is the design of receptor antagonists. Several published melanocortin receptor antagonists were developed by systematic modification of cyclic melanocortin agonist scaffolds including PT-141 and MT-II.
SHU9119, for example, is a widely used MC3R/MC4R antagonist derived from cyclic melanocortin peptide SAR. Key modifications in its design include substitution of the D-Phe position with D-2-naphthylalanine (D-Nal(2')) and other changes that shift the pharmacological outcome from agonism to antagonism despite retaining receptor binding affinity.
This demonstrates a broader principle: within the cyclic melanocortin scaffold, the boundary between agonism and antagonism is determined by specific structural features that influence how the bound peptide stabilizes the active versus inactive receptor conformation. Understanding this SAR landscape helps researchers select appropriate tool compounds and controls for their melanocortin system experiments.
Practical SAR Knowledge for Researchers Interpreting Published Data
Several practical implications of melanocortin peptide SAR are directly relevant to researchers using PT-141 as a tool compound:
1. Inter-lab EC50 variability is often structural, not technical. Published EC50 values for PT-141 at MC4R vary across studies. While assay format differences contribute, another source of apparent variability is the exact synthesis and purity of the PT-141 used. Small structural differences (incomplete cyclization, racemization at D-Phe, Met oxidation in Nle analogs) can shift potency. This is one reason that sourcing PT-141 from a supplier with documented synthesis quality and HPLC/MS verification is important for reproducing published benchmarks.
2. The pharmacophore is required for any claim of MCR activity. If you are characterizing a novel analog derived from PT-141's scaffold, any modification to His, D-Phe, Arg, or Trp requires careful re-validation of receptor binding before conclusions are drawn. These residues are not available for casual modification.
3. The C-terminal chemistry affects selectivity, not potency alone. Researchers sometimes assume that C-terminal modifications are minor and pharmacologically silent. For PT-141 vs. MT-II, the C-terminal amide vs. carboxyl difference is actually a meaningful selectivity determinant at MC1R. When working with novel analogs, do not assume the C-terminal modification is pharmacologically neutral.
Summary: Key PT-141 SAR Principles
| Structural Feature | Effect on Receptor Pharmacology |
|---|---|
| His-D-Phe-Arg-Trp pharmacophore | Essential for all MCR binding; required |
| D-Phe vs. L-Phe | D-configuration required for high affinity; L-form greatly reduces activity |
| Nle for Met substitution | Maintains activity; improves metabolic stability |
| Cyclic lactam bridge | Required for conformational rigidity and enhanced binding; ring size is optimized |
| C-terminal carboxyl (-OH, PT-141) | Reduces MC1R activity vs. amide (-NH₂, MT-II) |
| Trp position modifications | Can shift MC3R vs. MC4R selectivity |
Related Research Resources in This Cluster
- Palmetto Peptides Guide to the Research Peptide PT-141 (Bremelanotide)
- PT-141 Chemical Structure, Sequence, and Molecular Properties for Research Use
- PT-141 Mechanism of Action as a Melanocortin Receptor Agonist in Preclinical Research
- PT-141 vs Melanotan II: Comparative Analysis for Research Peptide Applications
- Using PT-141 in Radioligand Binding and Cell-Based Receptor Assays: A Research Applications Guide
- History of PT-141 Research Peptide: From Melanotan II Discoveries to Modern Laboratory Applications
Frequently Asked Questions
Q: What is the core pharmacophore of PT-141? The His-D-Phe-Arg-Trp tetrapeptide sequence, essential for MC3R/MC4R binding and conserved in all active cyclic melanocortin analogs.
Q: Why is D-phenylalanine critical? It provides hydrophobic contacts in the receptor binding pocket, and the D-stereochemistry is specifically required for optimal receptor engagement. L-Phe substitution substantially reduces binding affinity.
Q: How does the cyclic lactam structure affect binding? It pre-organizes the pharmacophore in a receptor-favorable conformation, increasing binding affinity and reducing proteolytic susceptibility compared to linear analogs.
Q: Can PT-141 be modified for MC4R vs. MC3R selectivity? Published SAR work indicates the tryptophan position influences relative MC3R/MC4R selectivity. Modifications require careful re-validation before selectivity conclusions are drawn.
Q: How does SAR knowledge guide compound selection? It helps researchers choose appropriate controls, interpret inter-study variability, understand PT-141 vs. MT-II differences, and recognize why compound quality (purity, stereochemistry) is critical for reliable data.
Citations
Hruby VJ, et al. "Cyclic lactam alpha-melanotropin analogues." Journal of Medicinal Chemistry. 1995;38:3454-3461.
Haskell-Luevano C, Cone RD. "Melanocortin ligands: 30 years of structure-activity relationship (SAR) studies." Medicinal Research Reviews. 2011;31(5):654-696.
Bednarek MA, et al. "Structure-function studies on the cyclic peptide MT-II, lactam derivative of alpha-MSH." Peptides. 1999;20(4):401-409.
Ewing GW. "Structure-activity relationships of the melanocortin peptides." Journal of Peptide Science. 2010;16:1-12.
Wikberg JE. "Melanocortin receptors: new opportunities in drug discovery." Expert Opinion on Therapeutic Patents. 2001;11(1):61-76.
Author: Palmetto Peptides Research Team
For scientific and educational reference only. PT-141 is a research peptide sold exclusively for qualified laboratory use. Not for human or veterinary use.
Part of the PT-141 Research Guide — Palmetto Peptides comprehensive research resource.